Read More Healthcare Industry News ZimVie investors back $19 a share ARCHIMED deal, setting stage for major medtech shake-up Find out how ZimVie’s shareholders approved a $19-per-share ARCHIMED acquisition and what it means for medtech investors and M&A sentiment. bySoujanya RaviOctober 10, 2025